Quoin Pharmaceuticals LT-ADRQNRX
13F holders, Q1 2026 (March 31)At the end of Q1 2026, 21 institutions reported holding Quoin Pharmaceuticals LT-ADR (QNRX) in their 13F filings, up 3 from Q4 2025. 6 opened new positions and 3 sold out. The largest holders were Ikarian Capital, LLC ($1.4M), Dauntless Investment Group, LLC ($1.3M) and SummitTX Capital, L.P. ($662K). 2 famous investors held it, including Israel Englander (0.0% of Millennium Management's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Quoin Pharmaceuticals LT-ADR
- CUSIP
- 74907L409
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $2.2M |
| Exits | 3 | $1.5M |
All 13F filers, Q4 2025 → Q1 2026: 473,055 shares bought and 131,161 shares sold, net +341,894 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 21 holders
| Ikarian Capital, LLC | 0.20% | No change | 211,538 | $1.4M |
| Dauntless Investment Group, LLC | 3.65% | New | 196,592 | $1.3M |
| SummitTX Capital, L.P. | 0.02% | Add +54.8% | 100,300 | $662K |
| Velan Capital Investment Management LP | 0.35% | New | 84,849 | $560K |
| Woodline Partners LP | 0.00% | No change | 79,582 | $525K |
| Millennium Management | 0.00% | Add +1.9% | 76,247 | $503K |
| Aberdeen Group plc | 0.00% | No change | 75,000 | $495K |
| Soleus Capital Management, L.P. | 0.02% | Add +190.9% | 72,730 | $480K |
| Centiva Capital, LP | 0.02% | Add +397.8% | 60,000 | $396K |
| Boothbay Fund Management, LLC | 0.01% | No change | 59,838 | $395K |
| Stonepine Capital Management, LLC | 0.31% | Reduce -31.6% | 53,460 | $353K |
| AIGH Capital Management LLC | 0.07% | Add +3.4% | 51,000 | $337K |
| Citadel Advisors | 0.00% | New | 32,519 | $215K |
| Birchview Capital, LP | 0.08% | New | 20,000 | $132K |
| Morgan Stanley | 0.00% | Add +33.3% | 4,000 | $26K |
| UBS Group AG | 0.00% | Add +14676.5% | 2,512 | $17K |
| GAMMA Investing LLC | 0.00% | Reduce -17.5% | 1,720 | $11K |
| Rhumbline Advisers | 0.00% | Reduce -8.7% | 1,521 | $10K |
| Barclays PLC | 0.00% | New | 1,300 | $9K |
| SBI Securities Co., Ltd. | 0.00% | Reduce -99.2% | 2 | $13 |
| Royal Bank of Canada | 0.00% | New | 11 | $0 |
"% of holder's portfolio" is QNRX's weight in each manager's 13F, not the share of Quoin Pharmaceuticals LT-ADR the manager owns.